Search Results for: cronos
Cronos Group and Ginkgo Bioworks Announce Achievement of Equity Milestone in Partnership to Produce Cultured Cannabinoids
Cronos Group, Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks (“Ginkgo”),…
Cronos Group Inc. to Speak at the Canaccord Genuity 41st Annual Growth Conference
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global…
Cronos Group Reports 2021 Second Quarter Results
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2021…
Cronos Group Launches Delicious New Dual-Flavor Cannabis Gummies
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), announces the launch…
Cronos Group Inc. to Hold 2021 Second Quarter Earnings Conference Call on August 6, 2021
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its…
Cronos Group invests $110.4 million, takes 10.5% ownership PharmaCann
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”) and PharmaCann Inc. (“PharmaCann”), one of…
Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks,…
Cronos Group Reports 2021 First Quarter Results
Receives processing license for the commercial production and sale of cannabinoids using biosynthesis Announces plans…
Cronos Group Inc. to Hold 2021 First Quarter Earnings Conference Call on May 7, 2021
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2021…
Cronos Group Reports 2020 Fourth Quarter and Full-Year Results
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2020 fourth…
Recent Comments